These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 17112877

  • 1. Suitable whole blood levels 2 hours after neoral in liver transplant patients: experiences at a single center.
    Kim KH, Lee SG, Lee YJ, Park KM, Hwang S, Ahn CS, Moon DB, Ha TY, Song KW, Kim DS, Jung DH, Kim BS, Moon KM, Lee HJ, Park JI, Ryu JH.
    Transplant Proc; 2006 Nov; 38(9):2971-3. PubMed ID: 17112877
    [Abstract] [Full Text] [Related]

  • 2. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 3. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
    Takatsuki M, Chen CL, Chen YS, Wang CC, Lin CC, Yang CH, Yong CC, Liu YW.
    Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
    [Abstract] [Full Text] [Related]

  • 4. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
    Ventura E, Bonardet A, Pageaux GP, Mourad G, Cristol JP.
    Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
    [Abstract] [Full Text] [Related]

  • 5. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E, Ruiz JC, Angeles de Cos M, Ruiz J, Gago M, Piñera C, Sánchez B, González-Cotorruelo J, Gómez-Alamillo C, Arias M.
    Transplant Proc; 2009 Mar; 41(6):2328-31. PubMed ID: 19715910
    [Abstract] [Full Text] [Related]

  • 6. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring.
    Ragette R, Kamler M, Weinreich G, Teschler H, Jakob H.
    J Heart Lung Transplant; 2005 Sep; 24(9):1315-9. PubMed ID: 16143250
    [Abstract] [Full Text] [Related]

  • 7. History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.
    Cantarovich M, Barkun J, Giannetti N, Cecere R, Besner JG, Tchervenkov J.
    Transplant Proc; 2004 Mar; 36(2 Suppl):442S-447S. PubMed ID: 15041383
    [Abstract] [Full Text] [Related]

  • 8. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A, Grant DR, Kneteman NM, Tchervenkov JI, Levy GA, Tan A, Hendricks L.
    Ann Chir; 1998 Mar; 52(8):716-21. PubMed ID: 9846420
    [Abstract] [Full Text] [Related]

  • 9. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
    [Abstract] [Full Text] [Related]

  • 10. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB, Ruttmann E, Geltner C, Bucher B, Nagiller J, Laufer G, Mueller LC.
    Clin Transplant; 2008 Oct; 22(1):35-40. PubMed ID: 18217903
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR, David OJ, Leaver N, Davis J, Breen J, Johnston A, Yacoub MH.
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [Abstract] [Full Text] [Related]

  • 12. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Aros CA, Schneider HO, Flores CA, Ardiles LG, Alruiz PA, Jerez V, Mezzano SA.
    Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
    [Abstract] [Full Text] [Related]

  • 13. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
    Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R.
    Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
    [Abstract] [Full Text] [Related]

  • 14. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G.
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [Abstract] [Full Text] [Related]

  • 15. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
    Strong DK, Lai A, Primmett D, White CT, Lirenman DS, Carter JE, Hurley RM, Virji M, Ensom MH.
    Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
    [Abstract] [Full Text] [Related]

  • 16. Neoral dose adjustment after conversion from C0 to C2 monitoring in stable renal transplant recipients: a prospective single center study.
    Sandrini S, Bossini N, Setti G, Mazzucchelli C, Maiorca P, Cancarini G.
    J Nephrol; 2004 Oct; 17(2):284-90. PubMed ID: 15293530
    [Abstract] [Full Text] [Related]

  • 17. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P, Kocher A, Neuhauser P, Sarahrudi K, Seweryn J, Wisser W, Klepetko W.
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [Abstract] [Full Text] [Related]

  • 18. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ.
    J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
    [Abstract] [Full Text] [Related]

  • 19. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
    Higgins RM, Kanji H, Hernon M, Harrison P, Lam FT, Kashi SH.
    Transpl Int; 2005 Jul; 18(7):806-10. PubMed ID: 15948859
    [Abstract] [Full Text] [Related]

  • 20. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
    Cole E, Deshpande R.
    Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.